The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
Open accessAbstract
Acutely ill medical patients are at heightened risk for venous thromboembolism, a term that combines deep vein thrombosis (DVT) and its more severe complication, pulmonary embolism.[ 1 ] [ 2 ] Although the incidence of venous thromboembolism in medical patients might have been overestimated in some instances, according to a recent study,[ 3 ] treatment by low, prophylactic doses of low molecular weight heparin (LMWH) is recommended for these patients when additional risk factors coexist.[ 1 ] [ 2 ] COVID-19 is an acute, complex disorder that is associated with SARS-CoV-2 infection, which, in its most severe presentation, is characterized by the development of interstitial pneumonia and acute respiratory distress syndrome.[ 4 ] According to many reports, COVID-19 exposes patients to a particularly high risk for venous thromboembolism.[ 5 ] [ 6 ] [ 7 ] [ 8 ] Hence, hospitalized COVID-19 patients are generally treated with higher LMWH doses than recommended for thromboprophylaxis. A recent document by the Italian Drug Agency (AIFA) suggested the use of 80 to 100 mg enoxaparin daily, instead of the usual 40 mg, while in some hospitals, even higher, up to full anticoagulant doses of LMWH or unfractionated heparin[ 9 ] are used. In our hospital we use 40 mg enoxaparin daily, as recommended for high-risk, acutely ill medical patients.[ 1 ] [ 2 ] From the COVID-19 outbreak in Northern Italy until April 14, 388 patients have been admitted to our non-intensive care unit (ICU) wards, none of whom developed symptomatic DVT during their hospital stay. As DVT may be asymptomatic in a proportion of patients at risk, we performed leg compression ultrasonography, which failed to detect DVT in any of the 64 tested patients, independently of the severity of their condition and length of in-hospital bed rest ([ Table 1 ]). The absence of reports in the literature of DVT in COVID-19 patients under LMWH thromboprophylaxis confirms our experience. This is apparently in contrast with the relatively frequent reports of pulmonary embolism in hospitalized COVID-19 patients,[ 5 ] [ 6 ] [ 7 ] [ 8 ] which is diagnosed based on the clinical observation of rapid worsening of respiratory insufficiency and blood oxygenation that is out of proportion to the extent of pulmonary infiltration and on the evidence of pulmonary vessel occlusions, generally interpreted as caused by pulmonary emboli, when computed tomography angiography (CTA) is performed. These patients, however, usually do not have symptoms or signs of DVT. As an example, a study of 184 severe COVID-19 patients, all hospitalized in ICU and treated mostly with standard doses of LMWH for thromboprophylaxis, reported a high incidence of venous thromboembolism ( n = 28).[ 5 ] However, only one patient had DVT (diagnosed by compression ultrasonography), while pulmonary embolism (diagnosed by CTA) was by far the most frequent thrombotic event ( n = 25) (highlighting the importance of performing CTA in symptomatic patients whenever possible), followed by two cases of catheter-related upper extremity venous thrombosis.[ 5 ] The discrepancy between the frequencies of pulmonary embolism and DVT is surprising, because, although pulmonary embolism may occur in the absence of detectable DVT, this happens in only approximately 20% of studied patients.[ 10 ] Therefore, we question whether the observed pulmonary vessels occlusions that have been described in reports on COVID-19 patients are exclusively caused by pulmonary embolism. In our experience and in some reports,[ 11 ] [ 12 ] filling defects of pulmonary vessels that are detected by CTA scans are in many instances more reminiscent of pulmonary thrombi rather than emboli, because they are not fully occlusive. This observation is compatible with postmortem descriptions of “…presence of manifestations of thrombotic, or thrombo-hemorrhagic microangiopathy…; …enlarged pulmonary blood vessels containing microthrombi….” Diffuse thrombotic material is observed also in other organs, compatibly with the development of clinical signs of multiorgan failure.[ 13 ] Therefore, local thrombi both in the lungs and other organs, rather than emboli from peripheral veins, appear to be the hallmark of severe COVID-19, which are responsible for the severe ischemic clinical manifestations of the disease. Table 1 Characteristics of 64 hospitalized COVID-19 patients who underwent bilateral leg compression ultrasonography to unravel asymptomatic deep vein thrombosis Age (y) 70 [min = 35; max = 97; IQR = 58–77.5] Days of in-hospital bed rest 9 [min = 1; max = 45; IQR = 4–15] Days in NIV 0 [min = 0; max = 20; IQR = 0–5] Respiratory rate (breaths/min) 20 [min = 8; max = 32; IQR = 16–24] PaO 2 /FiO 2 300 [min = 60; max = 600; IQR = 249–392.5] D-dimer (µg/mL) 0.458 [min = 0.1; max = 11.970; IQR = 0.252–0.903] Fibrinogen (g/L) 4.76 [min = 1.30; max = 9.50; IQR = 3.878–5.38] Ferritin (µg/L) 320 [min = 30; max = 9,000; IQR = 185–776] Prothrombin time (P/N ratio) 1.13 [min
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of thrombotic complications in critically ill ICU patients with COVID-19
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.013 · Cited by 5,028
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1091 · Cited by 3,903
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14817 · Cited by 3,559
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Platelet biology and functions: new concepts and clinical perspectives
van der Meijden, P. E. J., & Heemskerk, J. W. M. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0110-0 · Cited by 1,041
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study
Du, Y., Tu, L., Zhu, P., Mu, M., Wang, R., Yang, P., Wang, X., Hu, C., Ping, R., Hu, P., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0543oc · Cited by 942
Schünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022954 · Cited by 819
Acute pulmonary embolism and COVID-19 pneumonia: a random association?
Danzi, G. B., Loffi, M., Galeazzi, G., & Gherbesi, E. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa254 · Cited by 657
Jackson, S. P., Darbousset, R., & Schoenwaelder, S. M. (2019) · Blood · doi:10.1182/blood-2018-11-882993 · Cited by 616
Wang, J., Hajizadeh, N., Moore, E. E., McIntyre, R. C., Moore, P. K., Veress, L. A., Yaffe, M. B., Moore, H. B., & Barrett, C. D. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14828 · Cited by 536
Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19
Wang, T., Chen, R., Liu, C., Liang, W., Guan, W., Tang, R., Tang, C., Zhang, N., Zhong, N., & Li, S. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30109-5 · Cited by 376
Studies on the Pathogenesis of the Adult Respiratory Distress Syndrome
Mcguire, W. W., Spragg, R. G., Cohen, A. B., & Cochrane, C. G. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110480 · Cited by 357
Guo, L., & Rondina, M. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02204 · Cited by 224
ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A comment
Barrett, C. D., Moore, H. B., Yaffe, M. B., & Moore, E. E. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14860 · Cited by 219
Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography
Rotzinger, D. C., Beigelman-Aubry, C., von Garnier, C., & Qanadli, S. D. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.011 · Cited by 199
Ekdahl, K. N., Teramura, Y., Hamad, O. A., Asif, S., Duehrkop, C., Fromell, K., Gustafson, E., Hong, J., Kozarcanin, H., Magnusson, P. U., et al. (2016) · Immunological Reviews · doi:10.1111/imr.12471 · Cited by 160
Eriksson, O., Mohlin, C., Nilsson, B., & Ekdahl, K. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01590 · Cited by 155
Platelet toll-like receptors in thromboinflammation
Schattner, M. A. (2017) · Frontiers in bioscience · doi:10.2741/4576 · Cited by 92
Platelet CLEC-2: Roles Beyond Hemostasis
Tsukiji, N., Shirai, T., Osada, M., Inoue, O., Ozaki, Y., & Suzuki‐Inoue, K. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1604090 · Cited by 56
Coagulation factor XII regulates inflammatory responses in human lungs
Hesse, C., Sewald, K., Jonigk, D., Warnecke, G., Fieguth, H.-G., Maat, S. D., Maas, C., Bonella, F., Preissner, K., Weiss, B., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0904 · Cited by 50
Nilsson, B., Teramura, Y., & Ekdahl, K. N. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.009 · Cited by 30
Loffredo, L., Arienti, V., Vidili, G., Cogliati, C. B., Battaglia, S., Perri, L., Giulio, R. D., Bernardini, S., Summa, M. L., Sciacqua, A., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.020 · Cited by 26
Thrombotic microangiopathies: Similar presentations, different therapies
Appel, G. B. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17001 · Cited by 15
Cited by
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
Al-Samkari, H., Karp Leaf, R. S., Dzik, W. H., Carlson, J. C. T., Fogerty, A. E., Waheed, A., Goodarzi, K., Bendapudi, P. K., Bornikova, L., Gupta, S., et al. (2020) · Blood · doi:10.1182/blood.2020006520 · Cited by 1,351
Large-Scale Multi-omic Analysis of COVID-19 Severity
Overmyer, K. A., Shishkova, E., Miller, I. J., Balnis, J., Bernstein, M. N., Peters-Clarke, T. M., Meyer, J. G., Quan, Q., Muehlbauer, L. K., Trujillo, E. A., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2020.10.003 · Cited by 606
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
Nopp, S., Moik, F., Jilma, B., Pabinger, I., & Ay, C. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12439 · Cited by 489
Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis
Suh, Y. J., Hong, H., Ohana, M., Bompard, F., Revel, M.-P., Valle, C., Gervaise, A., Poissy, J., Susen, S., Hékimian, G., et al. (2021) · Radiology · doi:10.1148/radiol.2020203557 · Cited by 489
Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019
Jiménez, D., García-Sanchez, A., Rali, P., Muriel, A., Bikdeli, B., Ruiz-Artacho, P., Le Mao, R., Rodríguez, C., Hunt, B. J., & Monreal, M. (2021) · Chest · doi:10.1016/j.chest.2020.11.005 · Cited by 468
Metadata
- Authors
- Cattaneo, M., Bertinato, E. M., Birocchi, S., Brizio, C., Malavolta, D., Manzoni, M., Muscarella, G., & Orlandi, M.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2020-04-29
- Volume
- 120
- Issue
- 08
- Pages
- 1230-1232
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W3018782743
- Cited by
- 304
- References
- 23
- FWCI
- 37.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.